Wedbush Maintains Neutral on Biogen, Raises Price Target to $196

Benzinga Newsdesk www.benzinga.com Neutral 55.9%

Neg 0% Neu 55.9% Pos 0%

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $191 to $196.